2016
DOI: 10.1109/tnb.2016.2535380
|View full text |Cite
|
Sign up to set email alerts
|

Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer

Abstract: To enhance locoregional therapies for liver cancer treatment, we propose in this study a mathematical model to optimize the transcatheter arterial delivery of therapeutical agents. To maximize the effect of the treatment and minimize adverse effects on the patient, different mathematical models of the tumor growth are considered in this study to find the optimal number of the therapeutic drug-loaded magnetic nanoparticles to be administered. Three types of therapy models are considered, e.g., angiogenesis inhi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
4
1
1

Relationship

2
4

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 32 publications
0
13
0
Order By: Relevance
“…The short aggregate transversal stabilization time calculated is compatible with these higher velocities. Theoretical models exist to predict how many aggregates will be needed for one‐lobe embolization, but in vivo MRN experiments are needed to give an accurate estimate on the time required for one‐lobe embolization. Third, the efficacy of magnetic microbeads as an embolizing agent cannot be evaluated by the current study and, although it is expected to be equivalent to that of beads used for DEB‐TACE, only in vivo MRN experiments will allow to answer this question.…”
Section: Discussionmentioning
confidence: 99%
“…The short aggregate transversal stabilization time calculated is compatible with these higher velocities. Theoretical models exist to predict how many aggregates will be needed for one‐lobe embolization, but in vivo MRN experiments are needed to give an accurate estimate on the time required for one‐lobe embolization. Third, the efficacy of magnetic microbeads as an embolizing agent cannot be evaluated by the current study and, although it is expected to be equivalent to that of beads used for DEB‐TACE, only in vivo MRN experiments will allow to answer this question.…”
Section: Discussionmentioning
confidence: 99%
“…15 and 16). 40,41 Logistic and Gompertz model structures were applied under this assumption. A model structure displayed by Eq.…”
Section: Empirical Model Structures Describing Therapeutic Effectmentioning
confidence: 99%
“…16. Although as far as we know there is no clinical study that utilized this model framework, it has been used to perform simulations to optimize the delivery of therapeutic agents for enhancing targeted therapies for liver cancer 41 and to investigate the optimization of antiangiogenic treatment. 42 Immune system.…”
Section: Empirical Model Structures Describing Therapeutic Effectmentioning
confidence: 99%
See 1 more Smart Citation
“…Unfortunately, the results of various experimental and clinical studies (see [36] and the references cited therein) have not produced clear guidelines on how to proceed with combined therapies, in part due to the multitude of drugs presently available and patient-specific interactions of multiple drugs. Hence, mathematicians and physicians have turn towards the framework of optimal control to infer protocols, dosages and timings that maximise tumour reduction and minimise harmful side-effects [27,30,31,37,39]. To contribute to this effort, we study an optimal control problem with the model (1.1) as the state system, and as controls we work with the boundary nutrient supply w 1 = σ B , the cytotoxic coefficient w 2 = m(t) and the antiangiogentic coefficient w 3 = s(t).…”
Section: Introductionmentioning
confidence: 99%